Submitted:
10 July 2025
Posted:
23 July 2025
You are already at the latest version
Abstract
Keywords:
Chapter 1: Introduction to Necrotizing Fasciitis
1.1. Overview of Necrotizing Fasciitis
1.2. Pathophysiology
1.3. Historical Context
1.4. Clinical Variants and Presentations
1.5. Management Evolution
1.6. Importance of Multidisciplinary Care
1.7. Conclusions
Chapter 2: Historical Context and Evolution of Management Strategies for Necrotizing Fasciitis Since 1990
2.1. Introduction
2.2. Epidemiology and Pathophysiology
2.2.1. Epidemiological Trends
2.2.2. Pathophysiological Insights
2.3. Advances in Diagnostic Techniques
2.3.1. Clinical Diagnosis
2.3.2. Imaging Studies
2.4. Evolution of Treatment Strategies
2.4.1. Surgical Intervention
2.4.2. Antibiotic Therapy
2.4.3. Adjunctive Therapies
2.5. Multidisciplinary Approaches
2.6. Outcomes and Quality of Life
2.6.1. Mortality Rates
2.6.2. Long-Term Outcomes
2.7. Conclusions
Chapter 3: Evolution of Management Strategies for Necrotizing Fasciitis Since 1990
3.1. Introduction
3.2. Historical Context
3.2.1. Early Recognition and Diagnosis
3.3. Surgical Management
3.3.1. Aggressive Debridement
3.3.2. Evolution of Surgical Techniques
3.4. Antibiotic Therapy
3.4.1. Historical Antibiotic Protocols
3.4.2. Broader Spectrum Coverage
3.5. Adjunctive Therapies
3.5.1. Hyperbaric Oxygen Therapy
3.5.2. Intravenous Immunoglobulin
3.6. Multidisciplinary Approaches
3.7. Outcomes and Future Directions
3.7.1. Improved Survival Rates
3.7.2. Research and Innovation
3.8. Conclusions
Chapter 4: Management Strategies for Necrotizing Fasciitis: Evolution and Current Practices
4.1. Introduction
4.2. Surgical Management
4.2.1. Early Surgical Intervention
4.2.2. Debridement Techniques
4.3. Antibiotic Therapy
4.3.1. Empirical Antibiotic Regimens
4.3.2. Targeted Therapy
4.4. Adjunctive Therapies
4.4.1. Hyperbaric Oxygen Therapy
4.4.2. Intravenous Immunoglobulin
4.5. Multidisciplinary Care
4.5.1. Role of the Infectious Disease Specialist
4.5.2. Psychological Support
4.6. Outcomes and Prognostic Factors
4.6.1. Survival Rates and Morbidity
4.6.2. Prognostic Scoring Systems
4.7. Conclusions
Chapter 5: Advances in Management Strategies and Clinical Outcomes of Necrotizing Fasciitis Since 1990
5.1. Introduction
5.2. Historical Overview of Management Strategies
5.2.1. Surgical Intervention
5.2.2. Antibiotic Therapy
5.2.2.1. Shift in Antibiotic Strategies
5.2.2.2. Role of Pharmacogenomics
5.3. Adjunctive Therapies
5.3.1. Hyperbaric Oxygen Therapy
5.3.1.1. Clinical Evidence
5.3.2. Intravenous Immunoglobulin (IVIG)
5.3.2.1. Evidence and Controversies
5.4. Multidisciplinary Approaches
5.4.1. Enhanced Communication and Coordination
5.4.2. Comprehensive Patient Care
5.5. Clinical Outcomes and Long-Term Implications
5.5.1. Improved Survival Rates
5.5.2. Quality of Life Considerations
5.6. Conclusions
Chapter 6: Future Directions in the Management of Necrotizing Fasciitis
6.1. Introduction
6.2. Advances in Diagnostic Techniques
6.2.1. Molecular Diagnostics
6.2.2. Imaging Innovations
6.3. Novel Therapeutic Approaches
6.3.1. Adjunctive Therapies
6.3.2. Immunomodulatory Treatments
6.3.3. Antimicrobial Stewardship
6.4. Multidisciplinary Management
6.5. Psychosocial Considerations
6.6. Research Priorities
- Pathogen Identification: Continued exploration of the microbiological landscape of NF, including the role of polymicrobial infections and emerging pathogens, will enhance understanding and treatment.
- Pathophysiological Mechanisms: Investigating the molecular and immunological responses to infection can inform the development of targeted therapies and preventive strategies.
- Long-Term Outcomes: Longitudinal studies examining the long-term physical and psychosocial outcomes of NF survivors will provide insights into the recovery process and inform post-discharge care.
- Quality Improvement Initiatives: Evaluating the effectiveness of existing management protocols and identifying best practices through quality improvement initiatives can contribute to enhanced care delivery.
6.7. Conclusions
References
- Krishnan, S.; Shah, K.; Dhillon, G.; Presberg, K. 1995: FATAL PURPURA FULMINANS AND FULMINANT PSEUDOMONAL SEPSIS. Crit. Care Med. 2016, 44, 574. [Google Scholar] [CrossRef]
- Brandt, D.S.; Trapani, S. Purpura fulminans in children: A review of pathogenesis and treatment. Pediatr. Emerg. Care 2002, 18, 214–219. [Google Scholar] [CrossRef]
- Goldenberg, N.A. , & Manco-Johnson, M. J. Protein C deficiency. Haemophilia 2004, 10(s4), 49–56. [Google Scholar] [CrossRef]
- Faust, S.N.; Levin, M.; Harrison, O.B.; Goldin, R.D.; Lockhart, M.S.; Kondaveeti, S.; Heyderman, R.S. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. New Engl. J. Med. 2001, 345, 408–416. [Google Scholar] [CrossRef] [PubMed]
- Levi, M.; Ten Cate, H.; van der Poll, T. Disseminated intravascular coagulation: State of the art. Thromb. Haemost. 2003, 91, 9–17. [Google Scholar] [CrossRef]
- Misset, B.; Timsit, J.F. , Chevret, S., Renaud, B., & Wolff, M. Outcomes of patients with purpura fulminans. Intensive Care Med. 2007, 33, 1033–1041. [Google Scholar] [CrossRef]
- Thompson, M.J. , Ninis, N., Perera, R., Mayon-White, R., Phillips, C., Bailey, L., & Levin, M. Clinical recognition of meningococcal disease in children and adolescents. Lancet 2006, 367, 397–403. [Google Scholar] [CrossRef]
- Weber, M.L. , Tinsley, M.K., & Bell, M.J. Purpura fulminans: Recognition, diagnosis and management. Curr. Opin. Pediatr. 2012, 24, 307–312. [Google Scholar] [CrossRef]
- Centers for Disease Control and Prevention (CDC). Meningococcal Disease: Technical and Clinical Information.
- World Health Organization. (2018). Meningococcal meningitis fact sheet.
- Nadel, S. (2007). Treatment of meningococcal disease. J. Infect. 2019, 54, 14–19. [Google Scholar] [CrossRef]
- Alhazzani, W.; Møller, M.H. , Arabi, Y. M., Loeb, M., Gong, M.N., Fan, E.,... & Rhodes, A. Surviving Sepsis Campaign: Guidelines for management of sepsis and septic shock. Intensive Care Medicine 2017, 43, 304–377. [Google Scholar] [CrossRef]
- Wong, H.R. , Cvijanovich, N. Z., Anas, N., Allen, G.L., Thomas, N.J., Bigham, M.T.,... Shanley, T.P. Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am. J. Respir. Crit. Care Med. 2012, 186, 934–939. [Google Scholar] [CrossRef]
- Toh, C.H. , & Alhamdi, Y. Current understanding of sepsis-induced coagulopathy and disseminated intravascular coagulation. Br. J. Haematol. 2021, 192, 643–656. [Google Scholar] [CrossRef]
- Driessen, G.J. , & van de Beek, D. Endothelial dysfunction in sepsis: Mechanisms and clinical relevance. Crit. Care 2012, 16, 235. [Google Scholar] [CrossRef]
- Hackett, S.J. , Ritchie, N. D., Andrews, M., & Pollard, A.J. Clinical features and outcome of children with meningococcal disease treated in a pediatric intensive care unit. Journal of Pediatrics 2001, 138, 709–715. [Google Scholar] [CrossRef]
- De Prost, N.; Tissières, P. Update on management of meningococcemia. Curr. Treat. Options Pediatr. 2016, 2, 1–14. [Google Scholar] [CrossRef]
- Dhooria, G.S. , & Aggarwal, R. Meningococcal disease in India: Under-recognized and under-reported. Indian J. Pediatr. 2013, 80, 343–349. [Google Scholar] [CrossRef]
- Hermans, P.W. , et al. Meningococcal endotoxin and host inflammatory response: Contribution to disease severity. Clin. Infect. Dis. 1999, 29, 48–53. [Google Scholar] [CrossRef]
- Berwick, D.M. , & Hackbarth, A. D. Eliminating waste in US health care. JAMA 2012, 307, 1513–1516. [Google Scholar] [CrossRef]
- McGillivray, D.; et al. A case of meningococcemia with purpura fulminans: Lessons in rapid recognition and response. Can. J. Emerg. Med. 2010, 12, 157–161. [Google Scholar] [CrossRef]
- Stevens, D.L. , Aldape, M. J., & Bryant, A.E. Life-threatening clostridial infections. Anaerobe 2012, 18, 254–259. [Google Scholar] [CrossRef]
- Brook, I. Microbiology and management of soft tissue and muscle infections. Int. J. Surg. 2002, 10, 203–208. [Google Scholar] [CrossRef] [PubMed]
- Smith-Slatas, C.L. , Bourque, M. , & Salazar, J.C. Clostridium sordellii soft tissue infections in children: Case report and review. Clin. Infect. Dis. 2006, 43, e14–e17. [Google Scholar] [CrossRef]
- Elliott, D.; Kufera, J.A. , & Myers, R. A. The microbiology of necrotizing soft tissue infections. Am. J. Surg. 2000, 179, 361–366. [Google Scholar] [CrossRef]
- Stevens, D.L. , & Bryant, A. E. Necrotizing soft-tissue infections. New Engl. J. Med. 2017, 377, 2253–2265. [Google Scholar] [CrossRef]
- Centers for Disease Control and Prevention (CDC). Clostridium perfringens infection: Gas gangrene. Retrieved from https://www.cdc.gov/clostridium-perfringens/index.html.
- Goldstein, E.J. C. , & Citron, D.M. Anaerobic infections and antimicrobial therapy. Anaerobe 2019, 13, 143–148. [Google Scholar] [CrossRef]
- May, A.K. , Stafford, R.E., Bulger, E.M., et al. Treatment of complicated skin and soft tissue infections. Surg. Infect. 2009, 10, 467–499. [Google Scholar] [CrossRef]
- Levison, M.E. , & Levison, J.H. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect. Dis. Clin. North Am. 2009, 23, 791–815. [Google Scholar] [CrossRef]
- Hakkarainen, T.W. , Kopari, N.M., Pham, T.N., & Evans, H.L. Necrotizing soft tissue infections: Review and current concepts in treatment, systems of care, and outcomes. Curr. Probl. Surg. 2014, 51, 344–362. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).